Abbott's New Sensor Can Read Two Things at Once. That's Never Been Done.
Abbott just got FDA authorization for the first wearable that continuously tracks both glucose and ketones simultaneously. For millions of diabetes patients at risk of a deadly complication called DKA, that second reading could be a game-changer.
A Wearable That Watches Two Clocks
Imagine your smoke detector could also sniff for carbon monoxide. Same device, same spot on the ceiling, but now it catches two deadly threats instead of one. That's essentially what Abbott just pulled off for diabetes care.
On August 25, 2026, the FDA authorized the Libre Duo 10 Day, the world's first wearable sensor that continuously tracks both glucose and ketones at the same time. No one has done this before. Every continuous glucose monitor (CGM) on the market today reads one thing: blood sugar. Abbott's new device reads two, and that second reading could be a lifesaver for millions of people.
The authorization came through the FDA's De Novo pathway, a regulatory route reserved for genuinely novel devices that don't fit into an existing product category. That alone tells you how new this is. There was no predicate device to compare it to because nothing like it existed.
Why Ketones Matter More Than You Think
Most people associate ketones with trendy keto diets. In diabetes, though, ketones are a warning flare.
When your body can't use glucose properly (because insulin is missing or not working), it starts burning fat for fuel instead. That process produces ketones. A little bit is fine. Too much, too fast, and you're headed toward diabetic ketoacidosis (DKA), a condition where your blood becomes dangerously acidic. DKA can escalate from "feeling off" to life-threatening within hours.
The tricky part: DKA doesn't always announce itself with high blood sugar. Some cases are euglycemic, meaning glucose levels look perfectly normal while ketones are quietly spiking. A standard CGM wouldn't catch that. It would be like watching only the speedometer while your engine temperature redlines.
Until now, the only way to check ketones was with separate blood or urine tests. Those are reactive by nature; you test after something feels wrong. Abbott's sensor flips that script by monitoring ketones continuously in the background, reading levels every minute alongside glucose.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Patients Who Need This Most
Two groups stand out as the clearest beneficiaries.
First: people using SGLT2 inhibitors. These blockbuster drugs (think Jardiance, Farxiga, Invokana) treat type 2 diabetes, heart failure, and kidney disease. They work brilliantly, but they carry a known DKA risk. Real-world data shows roughly 2.85 times the DKA risk after starting an SGLT2 inhibitor compared to certain other diabetes drugs. The absolute numbers are small, but when millions of people take these medications globally, "rare but serious" adds up fast.
Second: people on insulin pumps. Pump therapy delivers insulin continuously through a tiny catheter under the skin. If that infusion fails (a kinked tube, an air bubble, a dislodged site), insulin delivery stops abruptly. Ketones can start climbing before glucose rises enough to trigger an alarm. Having a sensor that watches both analytes simultaneously could catch pump failures earlier and buy patients critical time.
The device is cleared for people with diabetes ages 2 and older, which is notable. Pediatric patients with type 1 diabetes are among the most vulnerable to DKA, and parents of young kids with diabetes know the anxiety of overnight monitoring all too well.
What's Under the Hood
The Libre Duo 10 Day is a small sensor worn on the body for up to 10 days. It measures glucose and ketone levels in interstitial fluid (the liquid just beneath your skin) and sends readings wirelessly to a smartphone running Abbott's Libre app. The data also syncs with LibreView and LibreLinkUp, Abbott's cloud platforms that let clinicians and caregivers monitor remotely.
Abbott says the device meets two FDA standards simultaneously: iCGM (integrated continuous glucose monitoring) and the brand-new iCGK (integrated continuous glucose and ketone monitoring). That second standard didn't exist before because no device required it.
A European version, simply called Libre Duo, already has a CE Mark with up to 15 days of wear for adults 18 and older. The 10 Day version authorized in the U.S. covers a broader age range. Abbott plans to launch stateside later in 2026.
The Competitive Angle
The CGM market is a three-horse race: Abbott, Dexcom, and Medtronic. Each plays a slightly different game. Dexcom competes on sensor accuracy and premium positioning. Medtronic bundles its CGM with its insulin pump ecosystem. Abbott wins on scale, price accessibility, and pharmacy-channel distribution.
All three have been fighting over the same single metric: glucose accuracy. Market growth estimates range from roughly 13% to over 16% annually, depending on geography, keeping rivalry intense. But the battlefield has been shifting toward software, AI integration, and smartphone connectivity.
The Libre Duo 10 Day changes the conversation entirely. By adding a second analyte, Abbott isn't just iterating on glucose accuracy; it's redefining what a CGM can be. Competitors now face a strategic question: do they follow Abbott into multi-analyte sensing, or do they bet that glucose-only performance is enough?
For Abbott, the commercial logic is elegant. The same sensor, the same body real estate, the same app ecosystem, but with a new safety layer that targets high-risk patients. It's a differentiation play that doesn't require patients to wear anything extra.
The Road From Here
The big unknowns are real-world outcomes and reimbursement. Abbott's announcement makes a compelling case for intended benefit, but the data showing whether continuous ketone monitoring actually reduces DKA hospitalizations and healthcare costs will take time to accumulate. Analysts and clinicians will want to see those numbers before declaring victory.
Reimbursement is the other wildcard. Payers will need to decide how to cover a device that does something no device has done before. The De Novo pathway helps establish a regulatory foundation, but insurance coverage decisions follow their own timeline.
Still, the trajectory of this technology is hard to ignore. Scientists first proved that continuous ketone sensing in interstitial fluid was feasible in a 2021 pilot study, measuring BHB (the primary ketone body) over 14 days with a single calibration. Five years later, it's an FDA-authorized product. That's fast by medtech standards.
The broader implication goes beyond diabetes. If a tiny wearable sensor can reliably track two biomarkers at once, the door opens to tracking three, four, or more. Lactate for athletes. Cortisol for stress. Alcohol for clinical monitoring. Abbott may have just kicked open the door to an era where wearable sensors do what blood panels do today, one analyte at a time, without ever needing a needle.
For now, though, the win is simpler and more immediate: a small sensor on your arm that watches for two dangers instead of one. For the millions of people managing diabetes every day, that second set of eyes could make all the difference.
Deals & M&A4 min read
The Biotech Investor That Got Caught Peeking at the Answer Key
A federal court found RA Capital and Avilar Therapeutics guilty of willfully stealing a trade secret from Yale, awarding $4 million to Biohaven and the university. The verdict could reshape how biotech investors handle confidential academic science forever.
